-
Je něco špatně v tomto záznamu ?
Neuroprotective Riluzole-Releasing Electrospun Implants for Spinal Cord Injury
MM. Ullrich, B. Pulipaka, J. Yin, J. Hlinková, F. Zhang, MW. Chan, FJ. O'Brien, A. Dervan, K. Dziemidowicz
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- implantované léky MeSH
- kyselina glutamová metabolismus MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- neurony účinky léků MeSH
- neuroprotektivní látky * aplikace a dávkování chemie farmakologie MeSH
- polyestery chemie MeSH
- poranění míchy * farmakoterapie MeSH
- riluzol * aplikace a dávkování chemie farmakologie MeSH
- uvolňování léčiv MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Spinal cord injury (SCI) results in paralysis, driven partly by widespread glutamate-induced secondary excitotoxic neuronal cell death in and around the injury site. While there is no curative treatment, the standard of care often requires interventive decompression surgery and repair of the damaged dura mater close to the injury locus using dural substitutes. Such intervention provides an opportunity for early and local delivery of therapeutics directly to the injured cord via a drug-loaded synthetic dural substitute for localized pharmacological therapy. Riluzole, a glutamate-release inhibitor, has shown neuroprotective potential in patients with traumatic SCI, and therefore, this study aimed to develop an electrospun riluzole-loaded synthetic dural substitute patch suitable for the treatment of glutamate-induced injury in neurons. A glutamate-induced excitotoxicity was optimized in SH-SY5Y cells by exploring the effect of glutamate concentration and exposure duration. The most effective timing for administering riluzole was found to be at the onset of glutamate release as this helped to limit extended periods of glutamate-induced excitotoxic cell death. Riluzole-loaded patches were prepared by using blend electrospinning. Physicochemical characterization of the patches showed the successful encapsulation of riluzole within polycaprolactone fibers. A drug release study showed an initial burst release of riluzole within the first 24 h, followed by a sustained release of the drug over 52 days to up to approximately 400 μg released for the highest loading of riluzole within fiber patches. Finally, riluzole eluted from electrospun fibers remained pharmacologically active and was capable of counteracting glutamate-induced excitotoxicity in SH-SY5Y cells, suggesting the clinical potential of riluzole-loaded dural substitutes in counteracting the effects of secondary injury in the injured spinal cord.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015391
- 003
- CZ-PrNML
- 005
- 20250731090941.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.4c01270 $2 doi
- 035 __
- $a (PubMed)40378306
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ullrich, Mathilde M $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K
- 245 10
- $a Neuroprotective Riluzole-Releasing Electrospun Implants for Spinal Cord Injury / $c MM. Ullrich, B. Pulipaka, J. Yin, J. Hlinková, F. Zhang, MW. Chan, FJ. O'Brien, A. Dervan, K. Dziemidowicz
- 520 9_
- $a Spinal cord injury (SCI) results in paralysis, driven partly by widespread glutamate-induced secondary excitotoxic neuronal cell death in and around the injury site. While there is no curative treatment, the standard of care often requires interventive decompression surgery and repair of the damaged dura mater close to the injury locus using dural substitutes. Such intervention provides an opportunity for early and local delivery of therapeutics directly to the injured cord via a drug-loaded synthetic dural substitute for localized pharmacological therapy. Riluzole, a glutamate-release inhibitor, has shown neuroprotective potential in patients with traumatic SCI, and therefore, this study aimed to develop an electrospun riluzole-loaded synthetic dural substitute patch suitable for the treatment of glutamate-induced injury in neurons. A glutamate-induced excitotoxicity was optimized in SH-SY5Y cells by exploring the effect of glutamate concentration and exposure duration. The most effective timing for administering riluzole was found to be at the onset of glutamate release as this helped to limit extended periods of glutamate-induced excitotoxic cell death. Riluzole-loaded patches were prepared by using blend electrospinning. Physicochemical characterization of the patches showed the successful encapsulation of riluzole within polycaprolactone fibers. A drug release study showed an initial burst release of riluzole within the first 24 h, followed by a sustained release of the drug over 52 days to up to approximately 400 μg released for the highest loading of riluzole within fiber patches. Finally, riluzole eluted from electrospun fibers remained pharmacologically active and was capable of counteracting glutamate-induced excitotoxicity in SH-SY5Y cells, suggesting the clinical potential of riluzole-loaded dural substitutes in counteracting the effects of secondary injury in the injured spinal cord.
- 650 12
- $a riluzol $x aplikace a dávkování $x chemie $x farmakologie $7 D019782
- 650 12
- $a poranění míchy $x farmakoterapie $7 D013119
- 650 12
- $a neuroprotektivní látky $x aplikace a dávkování $x chemie $x farmakologie $7 D018696
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kyselina glutamová $x metabolismus $7 D018698
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a neurony $x účinky léků $7 D009474
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a implantované léky $7 D004343
- 650 _2
- $a polyestery $x chemie $7 D011091
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pulipaka, Bhavana $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), 123 St Stephens Green, Dublin 2 D02 YN77, Ireland
- 700 1_
- $a Yin, Jing $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K
- 700 1_
- $a Hlinková, Jana $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K $u Department of Tissue Engineering, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 142 20, Czechia $u Department of Biomaterials, Faculty of Dentistry, University of Oslo, Geitmyrsveien 69/71, PB 1142 Blindern, Oslo 0317, Norway
- 700 1_
- $a Zhang, Fangyuan $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K
- 700 1_
- $a Chan, Michael W $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K $1 https://orcid.org/0009000071761809
- 700 1_
- $a O'Brien, Fergal J $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), 123 St Stephens Green, Dublin 2 D02 YN77, Ireland $u Advanced Materials and Bioengineering Research Centre (AMBER), Trinity College Dublin, College Green, Dublin 2 D02 W9K7, Ireland
- 700 1_
- $a Dervan, Adrian $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), 123 St Stephens Green, Dublin 2 D02 YN77, Ireland $u Advanced Materials and Bioengineering Research Centre (AMBER), Trinity College Dublin, College Green, Dublin 2 D02 W9K7, Ireland
- 700 1_
- $a Dziemidowicz, Karolina $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K $1 https://orcid.org/0000000155015646
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 22, č. 6 (2025), s. 2905-2916
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40378306 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731090936 $b ABA008
- 999 __
- $a ok $b bmc $g 2366308 $s 1252516
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 22 $c 6 $d 2905-2916 $e 20250516 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20250708